A Phase 3 clinical trial evaluating 177Lu-edotreotide, a somatostatin-based peptide receptor radionuclide therapy, was updated on August 7, 2026. The trial, registered as NCT03049189 and titled "Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients," is designed to assess the compound in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NET).
According to the current record, the trial status is listed as active, not recruiting. This means the study is ongoing but is no longer enrolling new participants at this time. No results have been posted in connection with this update.
Somatostatin remains classified as an unapproved compound for research use, and 177Lu-edotreotide as studied here falls under investigational use in this Phase 3 program. The trial record does not provide efficacy or safety outcomes at this stage, only the current recruitment and phase status.
Additional details on the trial protocol, sponsor, and eligibility criteria can be found through the official clinical trial registry listing. Readers interested in the broader context of somatostatin research can consult the compound overview for more information.